Global API sourcing simplified
We connect API buyers and suppliers worldwide with speed, trust, and full transparency.

Filters

Filters
Filter
Custom request?
Type
Production region
Qualifications
Show more
Country of origin
Show more

Methocarbamol API from Chinese Manufacturers & Suppliers

14 verified results
Get full market intelligence report
Get full market intelligence report
Full access. Full negotiation power All Methocarbamol data. Full access. Full negotiation power

Commercial-scale Suppliers

Distributor
Produced in  China
|

Employees: 50+

|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: GMP
|
USDMF
|
MSDS
|
BSE/TSE
|
CoA

All certificates

GMP
USDMF
MSDS
BSE/TSE
CoA
Distributor
Produced in  India
|

Employees: 10

|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: GMP
|
FDA
|
MSDS
|
BSE/TSE
|
CoA

All certificates

GMP
FDA
MSDS
BSE/TSE
CoA
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Distributor
Produced in  World
|

Employees: 200+

|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: GMP
|
CEP
|
USDMF
|
MSDS
|
BSE/TSE

All certificates

GMP
CEP
USDMF
MSDS
BSE/TSE
CoA
Distributor
Produced in  India
|

Employees: 135+

|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: GMP
|
CoA

All certificates

GMP
CoA
Distributor
Produced in  China
|

Employees: 50+

|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: GMP
|
USDMF
|
ISO9001
|
CoA

All certificates

GMP
USDMF
ISO9001
CoA
Producer
Produced in  China
|

Employees: 400+

|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: GMP
|
MSDS
|
BSE/TSE
|
CoA

All certificates

GMP
MSDS
BSE/TSE
CoA
Get full market intelligence report
Get full market intelligence report
€399,-
All Methocarbamol data. Full access. Full negotiation power
Producer
Produced in  China
|
Audit Report: Click here for more information on Eurofins audit reports
Certifications: USDMF
|
CoA

All certificates

USDMF
CoA
Producer
Produced in  Taiwan
|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: USDMF
|
CoA

All certificates

USDMF
CoA
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Distributor
Produced in  India
|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: coa

All certificates

coa
Producer
Produced in  India
|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: GMP
|
coa

All certificates

GMP
coa
Producer
Produced in  China
|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: USDMF
|
CoA

All certificates

USDMF
CoA
Producer
Produced in  India
|
Audit Report: Click here for more information on Eurofins audit reports
Certifications: USDMF
|
EDMF/ASMF
|
ISO 9001
|
WC
|
KDMF

All certificates

USDMF
EDMF/ASMF
ISO 9001
WC
KDMF
coa
Not active
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Producer
Produced in  Unknown
|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: USDMF
|
CoA

All certificates

USDMF
CoA
Not active
Distributor
Produced in  China
|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: coa

All certificates

coa
Not active
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency Total market transparency
|
Supplier trade data access Supplier trade data access
|
Buyer / supplier flow comparison Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Procaps
Pfizer
Reckitt
Sanofi
Blau
Abbvie

Methocarbamol | CAS No: 532-03-6 | GMP-certified suppliers

A medication that provides short‑term relief of discomfort associated with acute, painful musculoskeletal conditions, supporting muscle spasm management for clinical and consumer markets.

Therapeutic categories

Acids, AcyclicBenzene DerivativesCarbamatesCarbamic Acid EstersCatecholsCentral Nervous System Agents
Generic name
Methocarbamol
Molecule type
small molecule
CAS number
532-03-6
DrugBank ID
DB00423
Approval status
Approved drug, Vet_approved drug
ATC code
M03BA73

Primary indications

  • Methocarbamol tablets and intramuscular injections are indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions
  • [Label,L6268] Oral methocarbamol in America may be given up to 1500mg 4 times daily for 2-3 days
  • In Canada, methocarbamol containing oral formulations are sold over the counter for pain associated with muscle spasm

Product Snapshot

  • Methocarbamol is available as an oral small‑molecule formulation and as injectable solutions for intramuscular or intravenous use
  • It is used as an adjunct for relief of discomfort associated with acute, painful musculoskeletal conditions and for muscle spasm–related pain
  • It is approved in the United States and Canada, with human and veterinary approvals in these markets

Clinical Overview

Methocarbamol (CAS 532-03-6) is a centrally acting skeletal muscle relaxant used for the symptomatic management of acute, painful musculoskeletal conditions. It was developed in the 1950s and is chemically classified as a guaiacol glyceryl ether within the broader anisole group. The compound received FDA approval in 1957 and is available in both oral and injectable forms. In the United States, it is prescribed as an adjunct to rest and physical therapy for short‑term relief of muscle spasm–related discomfort. In Canada, lower‑dose oral formulations may be supplied over the counter, including combinations with acetaminophen or ibuprofen, while products containing codeine remain prescription only.

Methocarbamol exhibits pharmacodynamic effects consistent with central nervous system depression. Although its mechanism is not fully defined, available data indicate inhibition of spinal polysynaptic reflexes and reduced nerve transmission within spinal and supraspinal pathways. It also prolongs the refractory period of muscle cells but does not directly affect muscle fiber contraction or peripheral neuromuscular transmission. In animal studies, it has shown anticonvulsant properties following electric shock.

Absorption, distribution, metabolism, and excretion characteristics are reported in the literature, but detailed quantitative parameters vary and are formulation dependent. The drug is generally considered to have a rapid onset of action with hepatic metabolism and renal elimination of metabolites.

Safety considerations include dose‑related central nervous system depression, with potential for drowsiness, dizziness, and impaired coordination. Caution is warranted in combination with other CNS depressants. Intramuscular or intravenous administration does not confer local anesthetic activity. Use in specific populations, including those with hepatic impairment and older adults, requires clinical judgment due to altered pharmacokinetic handling or increased sensitivity.

Brand and combination products vary by region, with long‑standing clinical use in musculoskeletal care settings.

For API procurement, suppliers should provide evidence of compliance with pharmacopoeial specifications, validated impurity controls, and stable manufacturing processes to support consistent quality across global regulatory environments.

Identification & chemistry

Generic name Methocarbamol
Molecule type Small molecule
CAS 532-03-6
UNII 125OD7737X
DrugBank ID DB00423

Pharmacology

SummaryMethocarbamol is a centrally acting skeletal muscle relaxant thought to exert its effect through general CNS depressant activity. It reduces spinal and supraspinal polysynaptic reflex transmission and may prolong the refractory period of muscle cells without directly affecting muscle fibers or neuromuscular transmission. The drug has been associated with carbonic anhydrase 1 as a molecular target, though its therapeutic relevance remains unclear.
Mechanism of actionThe mechanism of action of methocarbamol is thought to be dependant on its central nervous system depressant activity.This action may be mediated through blocking spinal polysynaptic reflexes, decreasing nerve transmission in spinal and supraspinal polysynaptic pathways, and prolonging the refractory period of muscle cells.Methocarbamol has been found to have no effect on contraction of muscle fibres, motor end plates, or nerve fibres.
PharmacodynamicsMethacarbamol is a skeletal muscle relaxant with an unknown mechanism of action.Methacarbamol has been shown to block spinal polysynaptic reflexes, decrease nerve transmission in spinal and supraspinal polysynaptic pathways, and prolong the refractory period of muscle cells.Methocarbamol does not act as a local anesthetic upon injection.In animal studies, methocarbamol also prevents convulsions after electric shock.
Targets
TargetOrganismActions
Carbonic anhydrase 1Humansinhibitor

ADME / PK

AbsorptionThe time to maximum concentration is 1.1 hours for both healthy patients and those on hemodialysis.The maximum plasma concentration is 21.3mg/L for healthy patients and 28.7mg/L in hemodialysis patients.The area under the curve for healthy patients is 52.5mg/L\*hr and 87.1mg/L*hr in hemodialysis patients.AUC% based on terminal elimination half life is 2% for healthy patients and 4% for hemodialysis patients. Older studies report maximum plasma concentrations in 0.5 hours.
Half-lifeThe elimination half life is 1.14 hours in healthy subjects and 1.24 hours in subjects with renal insufficiency.Older studies report half lives of 1.6-2.15 hours.
Protein bindingMethocarbamol is 46-50% protein bound in healthy patients and 47.3-48.9% protein bound in hemodialysis patients.
MetabolismMethocarbamol is metabolized in the liver by demethylation to 3-(2-hydroxyphenoxy)-1,2-propanediol-1-carbamate or hydroxylation to 3-(4-hydroxy-2-methoxyphenoxy)-1,2-propanediol-1-carbamate.Methocarbamol and its metabolites are conjugated through glucuronidation or sulfation.
Route of eliminationIn humans the majority of the dose is eliminated in the urine.In dogs, 88.85% of the dose is eliminated in urine and 2.14% in the feces.In rats, 84.5-92.5% of the dose is eliminated in the urine and 0-13.3% is eliminated in the feces.
Volume of distributionVolume of distribution data in humans is scarce. In horses, the volume of distribution is 515-942mL/kg at steady state or 724-1130mL/kg.
Clearance0.2-0.8L/h/kg.

Formulation & handling

  • Oral formulations are feasible due to good aqueous solubility and food-independent absorption, allowing straightforward tablet or capsule design.
  • Parenteral products require attention to solution stability and pH control to maintain solubility and prevent precipitation during IV/IM administration.
  • As a small-molecule solid with moderate hydrophilicity (logP ~0.45), it handles well in standard solid-dose manufacturing with minimal need for solubilizers.

Regulatory status

LifecycleThe API is marketed in Canada and the US, where patent expiry timing indicates a late‑stage lifecycle with established market competition. These factors suggest a mature market environment with limited remaining exclusivity.
MarketsCanada, US
Supply Chain
Supply chain summaryMethocarbamol is an established, off‑patent product with no active originator presence in the current supply data, and its market is dominated by numerous generic manufacturers and repackagers. Branded and combination products are available mainly in the US and Canada, reflecting mature global distribution. Patent expiry long ago supports the broad, ongoing generic competition seen across the supply chain.

Safety

ToxicityOverdose of methocarbamol may be associated with alcohol and other central nervous system depressants.[Label] Patients may experience nausea, drowsiness, blurred vision, hypotension, seizures, and coma.[Label] Treatment of overdose is generally through airway maintenance, monitoring urinary output, vital signs, and giving fluid intravenously if necessary.[Label] The oral LD50 in rats is 3576.2mg/kg. The FDA has classified methocarbamol as pregnancy category C.[Label] Animal and human studies have not been performed to determine the risks to a fetus, however fetal and congenital abnormalities have been reported.[Label] Methocarbamol is excreted in the milk of dogs, however it is unknown if this is also the case for humans.[Label] Caution should be exercised when taking methocarbamol while breastfeeding.[Label] Studies to assess the carcinogenicity, mutagenicity, or effects on fertility of methocarbamol have not been performed.[Label]
High Level Warnings:
  • CNS‑depressant toxicity is potentiated by co‑exposure to alcohol or other sedatives
  • Overdose manifestations include severe neurologic and cardiovascular depression (e
  • G

Methocarbamol is a type of Muscle relaxants


Muscle relaxants are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) commonly used to alleviate muscle spasms and promote muscle relaxation. These medications act on the central nervous system (CNS) or directly on muscle fibers to reduce muscle tone and tension.

Muscle relaxants can be classified into two main groups: spasmolytics and neuromuscular blockers. Spasmolytics primarily target the CNS to inhibit the transmission of nerve signals, thus reducing muscle spasms. They are often prescribed for conditions such as back pain, muscle strains, and spasms caused by neurological disorders.

Neuromuscular blockers, on the other hand, act at the neuromuscular junction to prevent the transmission of nerve impulses, resulting in temporary paralysis of skeletal muscles. These medications are primarily used during surgical procedures to induce muscle relaxation and facilitate intubation.

Commonly prescribed muscle relaxants include benzodiazepines, such as diazepam and lorazepam, which have sedative properties and can provide relief from muscle spasms. Another class of muscle relaxants is the centrally acting skeletal muscle relaxants, including carisoprodol and cyclobenzaprine, which work by affecting neurotransmitters in the CNS.

It is important to note that muscle relaxants can cause side effects such as drowsiness, dizziness, and impaired coordination. They should only be used under the guidance of a healthcare professional, and the dosage and duration of treatment should be strictly followed to avoid dependence or other complications.

In conclusion, muscle relaxants are pharmaceutical APIs used to alleviate muscle spasms and promote muscle relaxation. They are available in different forms and can target the CNS or directly act on muscle fibers. It is crucial to consult a healthcare professional for proper diagnosis, prescription, and monitoring when using muscle relaxants.


Methocarbamol (Muscle relaxants), classified under Skeletal muscle relaxants


Skeletal muscle relaxants are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are commonly used in the treatment of musculoskeletal conditions characterized by muscle spasms, stiffness, or tension. These medications work by targeting the central nervous system to reduce muscle activity and promote relaxation.

Skeletal muscle relaxants act on various receptors in the central nervous system, such as gamma-aminobutyric acid (GABA) receptors, to inhibit the transmission of nerve impulses and decrease muscle tone. This results in a reduction in muscle spasms, pain relief, and improved mobility.

There are different classes of skeletal muscle relaxants, including benzodiazepines, antispasmodics, and centrally acting muscle relaxants. Benzodiazepines, such as diazepam and lorazepam, exert their muscle relaxant effects by enhancing the activity of GABA receptors. Antispasmodics like cyclobenzaprine work by inhibiting the release of certain neurotransmitters involved in muscle contractions. Centrally acting muscle relaxants, such as baclofen and tizanidine, directly target the spinal cord to reduce muscle hyperactivity.

Skeletal muscle relaxants are commonly prescribed for conditions like muscle spasms, back pain, fibromyalgia, and multiple sclerosis. However, they are typically used for short-term treatment due to their potential side effects, including drowsiness, dizziness, and sedation.

It is important to note that skeletal muscle relaxants should only be used under the supervision and prescription of a qualified healthcare professional. Proper dosage and duration of treatment should be determined based on the patient's condition and medical history to ensure safe and effective use of these medications.



Methocarbamol API manufacturers & distributors

Compare qualified Methocarbamol API suppliers worldwide. We currently have 14 companies offering Methocarbamol API, with manufacturing taking place in 5 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.

SupplierTypeCountryProduct originCertificationsPortfolio
Producer
India India CoA, GMP19 products
Producer
Germany Unknown CoA, USDMF35 products
Distributor
Switzerland India CoA, GMP174 products
Distributor
United States World BSE/TSE, CEP, CoA, GMP, MSDS, USDMF441 products
Distributor
United States China BSE/TSE, CoA, GMP, MSDS, USDMF166 products
Producer
Taiwan Taiwan CoA, USDMF3 products
Distributor
China China CoA162 products
Distributor
China China CoA, GMP, ISO9001, USDMF757 products
Producer
China China BSE/TSE, CoA, GMP, MSDS34 products
Producer
India India CoA, EDMF/ASMF, ISO9001, KDMF, USDMF, WC9 products
Distributor
India India BSE/TSE, CoA, FDA, GMP, MSDS263 products
Distributor
India India CoA70 products
Producer
China China CoA, USDMF15 products
Producer
China China CoA, USDMF3 products

When sending a request, specify which Methocarbamol API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).

Use the list above to find high-quality Methocarbamol API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.

Frequently asked questions about Methocarbamol API


Sourcing

What matters most when sourcing GMP-grade Methocarbamol?
Key considerations include confirming GMP compliance and ensuring the manufacturer meets US and Canadian regulatory requirements. Assess the reliability of supply, as the market is dominated by multiple generic producers and repackagers. Verification of quality documentation and consistency across batches is important in a mature, widely distributed product category.
Which documents are typically required when sourcing Methocarbamol API?
Request the core API documentation set: CoA (14 companies), USDMF (8 companies), GMP (7 companies), MSDS (4 companies), BSE/TSE (4 companies). Confirm versions and validity dates match the destination market to avoid delays in qualification.
Which manufacturers are known to produce Methocarbamol API?
Known or reported manufacturers for Methocarbamol: Hänseler AG, Suzhou Lixin Pharmaceutical CO.,LTD., Pharm Rx Chemical Corp, Sinoway industrial Co.,Ltd, LGM Pharma, Tenatra Exports Private Limited. Evaluate their GMP history, scale, and regional coverage before requesting dossiers or allocating demand.
How can I request quotes for Methocarbamol API from GMP suppliers?
Submit quote requests through the supplier listings with your specs and required documents (specifications, target volume, delivery timeline, and destination). Providing consistent details upfront speeds comparable offers and clarifies technical feasibility.
Is a GMP audit report available for Methocarbamol manufacturers?
Audit reports may be requested for Methocarbamol: 2 GMP audit reports available. Confirm the scope and recency of any audit before relying on it for qualification decisions.
How many suppliers offer Methocarbamol API on Pharmaoffer?
Reported supplier count for Methocarbamol: 14 verified suppliers. Filter listings by certifications, regions, and delivery options to match your qualification plan.
Which countries are known to manufacture Methocarbamol API?
Production countries reported for Methocarbamol: China (6 producers), India (5 producers), Taiwan (1 producer). Knowing the manufacturing geography helps anticipate logistics lead times and import compliance needs.
Which certifications do suppliers of Methocarbamol usually hold?
Common certifications for Methocarbamol suppliers: CoA (14 companies), USDMF (8 companies), GMP (7 companies), MSDS (4 companies), BSE/TSE (4 companies). Always verify issuing authorities and expiry dates when reviewing audit packages.

Technical

What is Methocarbamol (CAS 532-03-6) used for?
Methocarbamol is used for short‑term relief of acute, painful musculoskeletal spasms. It is typically prescribed as an adjunct to rest and physical therapy. In some regions, lower‑dose oral combinations with analgesics are available for similar symptomatic management.
Which therapeutic class does Methocarbamol fall into?
Methocarbamol belongs to the following therapeutic categories: Acids, Acyclic, Benzene Derivatives, Carbamates, Carbamic Acid Esters, Catechols. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.
What conditions is Methocarbamol mainly prescribed for?
The primary indications for Methocarbamol: Methocarbamol tablets and intramuscular injections are indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions, [Label,L6268] Oral Methocarbamol in America may be given up to 1500mg 4 times daily for 2-3 days, In Canada, Methocarbamol containing oral formulations are sold over the counter for pain associated with muscle spasm. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.
How does Methocarbamol work?
The mechanism of action of Methocarbamol is thought to be dependant on its central nervous system depressant activity.This action may be mediated through blocking spinal polysynaptic reflexes, decreasing nerve transmission in spinal and supraspinal polysynaptic pathways, and prolonging the refractory period of muscle cells.Methocarbamol has been found to have no effect on contraction of muscle fibres, motor end plates, or nerve fibres.
What should someone know about the safety or toxicity profile of Methocarbamol?
Methocarbamol produces dose‑related central nervous system depression, with common manifestations such as drowsiness, dizziness, and impaired coordination. Its depressant effects are enhanced by alcohol or other sedatives, increasing the risk of profound neurologic and cardiovascular depression, particularly in overdose. Caution is advised in populations with altered drug handling, such as older adults or those with hepatic impairment, due to increased sensitivity.
What are important formulation and handling considerations for Methocarbamol as an API?
Important considerations include leveraging its good aqueous solubility and food‑independent absorption to support conventional tablet or capsule formulations with standard excipients. For parenteral products, maintaining appropriate pH and solution stability is essential to prevent precipitation during IV or IM administration. The compound’s moderate hydrophilicity allows routine solid‑dose handling with minimal need for specialized solubilizers.
Is Methocarbamol a small molecule?
Methocarbamol is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.
Are there special stability concerns for oral Methocarbamol?
Oral Methocarbamol has good aqueous solubility and handles well in standard solid‑dose manufacturing, so it generally does not present unusual stability challenges. Tablets or capsules can be formulated without specialized solubilizers, and typical solid‑state stability controls are adequate. No formulation‑specific issues beyond standard protection from moisture and routine storage conditions are indicated.

Regulatory

Where is Methocarbamol approved or in use globally?
Methocarbamol is reported as approved in the following major regions: Canada, US. Understanding geographic coverage informs regulatory filings, supply planning, and risk assessments before escalating procurement.
What’s the regulatory and patent landscape for Methocarbamol right now?
In the United States and Canada, Methocarbamol is an approved active pharmaceutical ingredient with established regulatory pathways for generic products. The provided context does not indicate any active patent protections associated with the ingredient. As presented, its regulatory status reflects routine oversight within both markets without reference to exclusivity barriers.

Pharmaoffer

How does Pharmaoffer’s Smart Sourcing Service help with Methocarbamol procurement?
Pharmaoffer's Smart Sourcing Service coordinates compliant suppliers, documentation, and competitive quotes for Methocarbamol. It centralizes outreach, follow-ups, and document validation to shorten procurement timelines.
Is Methocarbamol included in the PRO Data Insights coverage?
PRO Data Insights coverage for Methocarbamol: 1478 verified transactions across 323 suppliers and 138 buyers worldwide. Use the dataset to benchmark suppliers and monitor regulatory activity where available.
Where can I access the API market report for Methocarbamol?
Market report availability for Methocarbamol: Report Available. The report highlights demand trends, pricing drivers, and supplier landscape insights for procurement planning.